Journal article
Refine
Has Fulltext
- yes (230)
Is part of the Bibliography
- yes (230)
Year of publication
Document Type
- Journal article (230) (remove)
Keywords
- Toxikologie (112)
- DNA damage (11)
- Adenosine receptors (8)
- DNA (5)
- DNA binding (5)
- Genotoxicity (5)
- oxidative stress (5)
- Adenylate cyclase (4)
- G proteins (4)
- Pharmakologie (4)
- heart failure (4)
- metabolism (4)
- micronuclei (4)
- Carcinogen (3)
- Carcinogenesis (3)
- Carcinogenicity (3)
- ERK1/2 (3)
- Enzyme induction (3)
- Medizin (3)
- Micronuclei (3)
- apoptosis (3)
- cytoskeleton (3)
- fluorescence resonance energy transfer (3)
- inflammation (3)
- mycotoxin (3)
- signal transduction (3)
- vitamin B6 (3)
- 1 (2)
- 5-Azacytidine (2)
- A1 adenosine receptors (2)
- Aflatoxin (2)
- Ames test (2)
- Carcinogens (2)
- DNA repair (2)
- Diethylstilbestrol (2)
- Dose response (2)
- Dose-response relationship (2)
- Electropermeabilization (2)
- Ernährung (2)
- Estrogen (2)
- G protein-coupled receptors (2)
- G-protein (2)
- GPCR (2)
- Hormone (2)
- N-formyl peptides (2)
- Pharmazie (2)
- RKIP (2)
- Radioligand binding (2)
- Rat (2)
- Reproductive toxicity (2)
- Salmonella/microsome assay (2)
- Silicones (2)
- actin (2)
- actinomycetes (2)
- adenosine receptors (2)
- barbiturates (2)
- biased signaling (2)
- biomedicine, general (2)
- calcium (2)
- cancer (2)
- cancer risk (2)
- cell biology (2)
- comet assay (2)
- cytokinins (2)
- differentiation (2)
- environmental health (2)
- familial DCM (2)
- heart (2)
- iPSC-cardiomyocytes (2)
- immunohistochemistry (2)
- in-vivo (2)
- insulin (2)
- kidneys (2)
- lymphocytes (2)
- mast cells (2)
- medicine (2)
- membrane skeleton (2)
- meningitis (2)
- nephrotoxicity (2)
- occupational medicine/industrial medicine (2)
- pharmacology/toxicology (2)
- phosphorylation (2)
- pneumolysin (2)
- pyridoxal phosphatase (2)
- rat brain membranes (2)
- risk assessment (2)
- therapy (2)
- transcription factors (2)
- yam (2)
- (Mouse L-cell) (1)
- (Rat brain membrane) (1)
- (Rat liver) (1)
- (Salmonella) (1)
- 18F-FDG (1)
- 2',7'-dichlorofluorescin (1)
- 2-Acetylaminofluorene (1)
- 2-Dichloroethane (1)
- 2-Dioxetane (1)
- 2-Generation reproduction (1)
- 3R (1)
- 4'-hydroxylation (1)
- 4-(p-nitrobenzyl)pyridine (1)
- 6-benzylaminopurine (1)
- 8-Hydroxy-deoxyguanosine (1)
- A(2B) receptors (1)
- A1 (1)
- A1 Adenosine receptors (1)
- A<sub>2</sub> Adenosine receptor (1)
- AMPK (1)
- A\(_{2A}\) adenosine receptor antagonist (1)
- Adenosine receptor (1)
- Adenosine receptor antagonists (1)
- Adenosinrezeptor (1)
- Aflatoxin B1 (1)
- Alkylation (1)
- Alzheimers disease (1)
- Amino acid composition (1)
- Amino acids (1)
- Anabolieagent (1)
- Aniline derivatives (1)
- Anthraquinone glycosides (1)
- Aryl hydrocarbon rnonooxygenase (1)
- Atria (1)
- B cells (1)
- BETA(2)-adrenergic receptor (1)
- Barbiturates (1)
- Barth syndrome (1)
- Benzefuran dioxetane (1)
- Benzefuran epoxide (1)
- Benzene (1)
- Benzo(a)pyrene-DNA binding (1)
- Berenil (1)
- Beta(1)-adrenergic receptor (1)
- Beta(2)-adrenergic receptor (1)
- Biomarkers (1)
- Bromodeoxyuridine labeling (1)
- C1q/TNF related protein (CTRP) (1)
- CIB1 (1)
- CRISPR Cas9 (1)
- CRISPR/Cas9 (1)
- CaMKII (1)
- Calcium (1)
- Cancer prevention (1)
- Carcinogen risk Individual susceptibili (1)
- Carcinogenic potency (1)
- Cardiac myocyte ; Beta-Receptor ; Muscarinic receptor ; cAMP ; G-protein ; Serum (1)
- Cell death and comet assay (1)
- Cell transformation (1)
- Chemical carcinogenesis (1)
- Chemotactic receptors (1)
- Choline deficiency (1)
- Chromosome aberration (1)
- Chromosome distribution (1)
- Chronic heart-failure (1)
- Covalent DNA binding (1)
- Covalent binding (1)
- Covalent binding index - Diethylstilbestrol (1)
- Cyclic AMP (1)
- Cytochrome b5 (1)
- DAMGO (1)
- DCM genetic background (1)
- DES (1)
- DNA Binding (1)
- DNA adduct . Repair endonuclease (1)
- DNA binching (1)
- DNA damage response (1)
- DNA metabolism (1)
- DNA methylation (1)
- DNA transfection (1)
- DNA-Binding (1)
- DNS-Schädigung (1)
- Dermatologie (1)
- Dietary process-related contaminants (1)
- Diisononyl phthalate (1)
- Dioscorea (1)
- Drug resistance (1)
- ERK signaling (1)
- Electric Field (1)
- Electrical breakdown (1)
- Electrophiles (1)
- Elektrofusion (1)
- Elektroporation (1)
- Emodin (1)
- Endogenous genotoxicity (1)
- Epoxide hydrolase (1)
- Estrone (1)
- Ethionine (1)
- Eukaryotic cell (1)
- External exposure assessment (1)
- FCS (1)
- FPG protein (1)
- FRET (1)
- Fabry Disease (FD) (1)
- Fischer 344 rats (1)
- Flow cytometry (1)
- Fluorescence resonance energy transfer (1)
- Friedreich’s ataxia (1)
- G protein coupled receptor (GPCR) (1)
- G protein-coupled receptor (1)
- G-protein coupled receptor (1)
- GABA-receptor complex (1)
- GPCRs (1)
- Gastric carcinogenesis (1)
- Gb3 and lyso-Gb3 biomarkers (1)
- Gene Transfer (1)
- Gene transfer (1)
- Genetic instability (1)
- Glutathione Stransferase (1)
- HIV infection (1)
- HPLC-MS/MS method (1)
- HeLa cells (1)
- High-throughput screening (1)
- Hoechst 33258 dye (1)
- Human platelets (1)
- Hybridoma (1)
- Immunization (1)
- Immunologie (1)
- In vitro toxicity testing (1)
- Inhalation (1)
- Ischemia/reperfusion (1)
- K + -channels (1)
- Kidneys (1)
- Kinetochore (1)
- Kinetochores (1)
- Krebs (1)
- Krebs <Medizin> (1)
- L5178Y cells (1)
- LTB4 receptor (1)
- Latrophilin (1)
- Leukocyte/endothelium interaction (1)
- Lung (1)
- MMQ cells (1)
- MammaJian mutagenicity test (1)
- Mechanism of action (1)
- Melanocortin 4 receptor (MC4R) (1)
- Melanocyte stimulating hormones MSH (1)
- Metabolism saturation (1)
- Microcirculation (1)
- Micronucleus formation (1)
- Micronucleus test (1)
- Mitosis (1)
- Molekularpharmakologie (1)
- Mutagenicity (1)
- Mutagenicity assay (1)
- Mutagens (1)
- Mutation assay (1)
- Myokarditis (1)
- N-methyl-N-nitrosourea (1)
- N1E 115 cells (1)
- Na\(_V\)1.8 (1)
- Neomycin Resistance (1)
- Nitrosation (1)
- Nitrosierung (1)
- OXPHOS (1)
- Oxidative stress (1)
- Oxygen radical (1)
- PBPK/PBTK model (1)
- PDE (1)
- PDE2 (1)
- PET (1)
- PKA (1)
- Phosphodiesterase (1)
- Photoaffinity labelling (1)
- Physiologically based kinetic models (1)
- Pointmutation (1)
- Prevalence (1)
- Prognostic impact (1)
- Prolactin (1)
- Protein binding (1)
- Protein coding (1)
- QIVIVE (1)
- Quantitative risk assessment (1)
- RBM20 mutations (1)
- ROS (1)
- Radiation inactivation (1)
- Radicals (1)
- Radioligand binding - 86Rb + -efflux (1)
- Radioligands (1)
- Radioligauds (1)
- Raman micro-spectroscopy (1)
- Rat Iiver microsomes (1)
- Rat liver peroxisome (1)
- Riot control agents (1)
- Risk assessment (1)
- Risk estimation (1)
- Risk-factors (1)
- SCN5a (1)
- ST-elevation myocardial infarction (1)
- Salmonella typhimurium (1)
- Sensitivity (1)
- Short-term Carcinogenicity Test (1)
- Short-term tests (1)
- Species differences (1)
- Spontaneous tumours (1)
- Stable Transformation (1)
- Streptomyces (1)
- T cells (1)
- TK6 cells (1)
- Target size (1)
- Theophylline (1)
- Thymidine glycol (1)
- Toluene (1)
- Toxin (1)
- Transfection (1)
- Transgenic mouse (1)
- Transgenie mice (1)
- Trenbolone (1)
- Tritiated Water (1)
- Unscheduled DNA synthesis (1)
- Uterine tumors (1)
- Valvular heart-desease (1)
- Venerologie (1)
- Volume distribution (1)
- Wachstumskonus (1)
- Water resources (1)
- Xanthines (1)
- Zelle (1)
- Zellskelett (1)
- [3H]PIA binding (1)
- absorption (1)
- actin cytoskeleton (1)
- activation (1)
- active zone (1)
- acute slices (1)
- adenine (1)
- adenosine (1)
- adenosine 3',5'-cyclic monophosphate (1)
- adenylate cyclase (1)
- adenylyl cyclase signaling cascade (1)
- adenylyl-cyclase isoforms (1)
- adhesion GPCR (1)
- adiponectin (1)
- adipose tissue (1)
- adult cardiac myocytes (1)
- adverse outcome pathway (1)
- adverse outcome pathway (AOP) (1)
- aflatoxin (1)
- ageing (1)
- agonists (1)
- aldosterone (1)
- alkylation (1)
- allelic variant (1)
- alternative methods (1)
- amine (1)
- amino acid (1)
- antagonists (1)
- anti-Parkinson agents (1)
- anti-inflammatory agents (1)
- antibacterial/antiviral drug (1)
- antibodies (1)
- antibody/autoantibody (1)
- antioxidants (1)
- aortocaval fistula model (1)
- aromatic amides (1)
- arrhythmia (1)
- arrhythmogenesis (1)
- assay (1)
- association (1)
- astrocytes (1)
- atopic eczema (1)
- atrial natriuretic peptide (1)
- avaliação de risco (1)
- bacterial meningitis (1)
- bariatric surgery (1)
- base excision repair (incision activity) (1)
- beta2-adrenoceptor knockout (1)
- beta3 CL 316,243 (1)
- binding (1)
- binding affinity (1)
- bioactive compounds (1)
- biofilms (1)
- biological techniques (1)
- biology (1)
- biomarker of exposure (1)
- biomarkers (1)
- blood coagulation factor XIII (1)
- blood plasma (1)
- blood pressure (1)
- blood samples (1)
- bone marrow (1)
- brain damage (1)
- brain membranes (1)
- cAMP (1)
- calcitonin gene-related peptide (1)
- calmodulin (1)
- carcinogen (1)
- cardiac hypertrophy (1)
- cardiac magnetic resonance imaging (1)
- cardiac myocyte ; muscarinic K current ; G-protein ; Albumin ; serum (1)
- cardiac remodelling (1)
- cardiomyocyte (1)
- cardiomyocytes (1)
- cardiovascular diseases (1)
- caveolin-1 (1)
- cell fate (1)
- cell fusion (1)
- cell proliferation (1)
- cell signalling (1)
- cell staining (1)
- chalcone (1)
- chemotactic receptors (1)
- chemotaxis (1)
- child health (1)
- cholesterol depletion (1)
- cholesterol-dependent cytolysin (1)
- chronic heart failure (1)
- chronic kidney disease (1)
- chronophin (1)
- cisplatin (1)
- classification (1)
- classification and labeling (1)
- clinical genetics (1)
- co-culture (1)
- coated vesicles (1)
- cognitive impairment (1)
- coherent anti-Stokes Raman scattering (CARS) microscopy (1)
- computational biophysics (1)
- conduction disease (1)
- conformational auto-epitope (1)
- conjugated mycotoxins (1)
- constitutive activity (1)
- contact lens (1)
- continuous (1)
- contractility (1)
- coumarin (1)
- coupled receptor (1)
- covalent binding (1)
- creatinine (1)
- crystal structure (1)
- cyclic AMP (1)
- cyclic dipeptide (1)
- cyclic nucleotides such as cyclic adenosine monophosphate (1)
- cyclic peptides/cyclopeptides (1)
- cyclic-AMP (1)
- cyclic-gmp (1)
- cyclopeptide therapy (1)
- cytochrome P450 2C9 (1)
- cytochrome P450s (1)
- cytome biomarkers (1)
- cytosol (1)
- cytotoxic (1)
- dCIRL (1)
- danio rerio (1)
- definition (1)
- dendritic spines (1)
- desensitization (1)
- detrusor muscle (1)
- developmental biology (1)
- diabetes (1)
- diagnosis (1)
- dialysis (1)
- dicyclohexyl phthalate (1)
- diet (1)
- dilated cardiomyopathy with ataxia (1)
- disrupting chemicals (1)
- disruptor endócrino (1)
- docking (1)
- domains (1)
- dormancy (1)
- down-regulation (1)
- drug (1)
- dunce (1)
- eccentric hypertrophy (1)
- ectodomain cleavage (1)
- efficient intervention points (1)
- endocrine disruptor (1)
- endogenous (1)
- energy-transfer (1)
- environmental phenols (1)
- enzyme-linked immunoassays (1)
- epigenetics (1)
- estrogen receptor (1)
- ethanol (1)
- etoposide (1)
- eugenol (1)
- exposição humana (1)
- exposure (1)
- fatty liver (1)
- fentanyl (1)
- fetal testis (1)
- fluorescence (1)
- fluorescence correlation spectroscopy (1)
- fluorescence detection (1)
- fluorescence imaging (1)
- fluorescence recovery after photobleaching (1)
- fluorescent probes (1)
- food contact materials (1)
- food safety (1)
- food security (1)
- formyl peptides (1)
- functional clustering (1)
- fungi (1)
- gastrointestinal cancer (1)
- general medicine (1)
- genetics (1)
- genomic damage (1)
- genotoxic (1)
- genotoxicity (1)
- genotypes (1)
- glucuronide (1)
- glutamate (1)
- glycolytic flux control (1)
- gravidez (1)
- growth cone (1)
- hA<sub>3</sub>AR (1)
- hOCT1 (1)
- haematopoietic stem cells (1)
- haloacid dehalogenase (1)
- haloacid dehalogenase-type phosphatase (1)
- healing and remodelling processes (1)
- hiPSC-CM (1)
- hidden mycotoxins (1)
- histamine release (1)
- homeostasis (1)
- homodimerization (1)
- hormone receptors (1)
- human (1)
- human A(3) (1)
- human biomonitoring (1)
- human exposure (1)
- human lung (1)
- hypertension (1)
- hypertonic solution (1)
- identification (1)
- impact pharmacogenetics (1)
- in vivo (1)
- indolylpyrimidylpiperazines (1)
- induced pluripotent stem cell cardiomyocytes (1)
- induced pluripotent stem cells (1)
- inflammatory diseases (1)
- insulin signaling (1)
- internalization (1)
- international union (1)
- intracellular loop (1)
- intrinsic metabolism (1)
- ionic look (1)
- ischemic stroke (1)
- isoproterenol (1)
- key event relationship (1)
- kinases (1)
- laminopathy (1)
- lamivudine (1)
- late Na\(^+\) current (I\(_{NaL}\)) (1)
- legislation (1)
- life (1)
- ligand binding (1)
- lipid rafts (1)
- lipidomics (1)
- listeriolysin O (1)
- live imaging (1)
- liver (1)
- liver microsomes (1)
- living vells (1)
- long-read sequencing (1)
- lovastatin (1)
- lysosomal disruption (1)
- lysosomal storage disorders (1)
- mTOR-inhibitor RAD-001 (1)
- maintenance of genomic integrity (1)
- major depression (1)
- male rats (1)
- mammalian genomics (1)
- marine sponges (1)
- masked mycotoxins (1)
- matrix metalloproteinase (1)
- maturation strategies (1)
- mechanotransduction (1)
- membrane (1)
- membrane transporters (1)
- memory B cells (1)
- mercapturic acid (1)
- metabotropic signalling (1)
- micronucleus test (1)
- microvessel permeability (1)
- mild (1)
- mitochondria (1)
- mitochondrial DNA polymerase γ (1)
- mitochondrial cardiomyopathy (1)
- mitotic disturbance (1)
- modelo PBPK/PBTK (1)
- modified mycotoxins (1)
- molecular biology (1)
- molecular dynamics (1)
- molecular modeling (1)
- molecular modelling (1)
- monogenetic cardiomyopathies (1)
- mortality (1)
- motor performance (1)
- mouse lymphoma L5178Y (1)
- mouse models DNA damage (1)
- mucosa (1)
- multivariate data analysis (1)
- mutagen (1)
- mutagenicity (1)
- mutant mice (1)
- mutation triggers (1)
- mycotoxin derivates (1)
- mycotoxin metabolites (1)
- mycotoxins (1)
- myocarditis (1)
- n-hexyl phthalate (1)
- nanopore (1)
- natural (1)
- neocortex (1)
- neurodegenerative diseases (1)
- neuronal dendrites (1)
- neurons (1)
- neuropsychiatric diseases (1)
- neurotransmitter biosynthesis (1)
- neutrophils (1)
- nitric-oxide (1)
- nitrosation (1)
- nitroso compound (1)
- no (1)
- nutritional composition (1)
- o-Chlorobenzylidene malononitrile (1)
- obesity (1)
- occurrence (1)
- ochratoxin A (1)
- octopamine (1)
- opioid ligands (1)
- optimal drug combination (1)
- optimal drug targeting (1)
- optimal pharmacological modulation (1)
- optimal treatment strategies (1)
- organ toxicity (1)
- parathyroid hormone 1 receptor (1)
- partial agonists (1)
- performance liquid-chromatography (1)
- peripheral nerve (1)
- peripheral-blood lymphocytes (1)
- personalized treatment (1)
- perspectives (1)
- pharmacogenetics (1)
- phosphoglycolate phosphatase (1)
- phosphoinositides (1)
- photoaffinity labelling (1)
- plasma membrane (1)
- poly(ADP-ribosyl)ation (1)
- pore formation (1)
- pore-forming toxin (1)
- positron emission tomography (1)
- potent (1)
- pregnancy (1)
- primary aromatic amine (1)
- protein (1)
- protein alkylation (1)
- protein design (1)
- protein-coupled receptors (1)
- protein-coupled-receptors (1)
- psoriasis (1)
- psychiatric disorders (1)
- purine derivatives (1)
- pyrrolizidine alkaloids (1)
- quantitative assessments (1)
- radiation (1)
- radii (1)
- radioligand (1)
- radioligand binding (1)
- rat pheochromocytoma cells (1)
- receptor binding (1)
- receptor pharmacology (1)
- receptor solubilization (1)
- receptor-G protein coupling (1)
- receptor-G protein coupling. (1)
- receptors (1)
- regulation (1)
- relaxation (1)
- reproductive and developmental toxicity (1)
- resveratrol (1)
- risk-assesment (1)
- sensory physiology (1)
- serum (1)
- sex (1)
- sexual development (1)
- signaling microdomain (1)
- simulated digestion (1)
- single-molecule microscopy (1)
- solid-phase extraction (1)
- solubilization (1)
- sponges (1)
- spontaneously hypersensitive-rats (1)
- staphilococci (1)
- statins (1)
- stomach (1)
- streptomyces (1)
- sub-Saharan Africa (1)
- subtypes (1)
- sugars (1)
- synapses (1)
- synaptic plasticity (1)
- tMCAO (1)
- tandem mass-spectrometry (1)
- targets (1)
- testosterone production (1)
- therapeutic potential (1)
- thyroid hormone (1)
- tissue (1)
- tolbutamide substrate (1)
- toxicocinética (1)
- toxicokinetics (1)
- toxicology (1)
- trans-Golgi network (1)
- transgenic animals (1)
- triazolotriazine derivatives (1)
- tuber (1)
- ultrastructure (1)
- urea (1)
- uremic toxins (1)
- variocosities (1)
- vitamin-D-receptor (1)
- volume overload (1)
- warfarin polymorphisms (1)
- weight of evidence (1)
- yellow fluorescent protein (1)
- µ-Opioid receptor (1)
- β-adrenergic receptors (1)
- β1-adrenoceptor/β1-adrenergic receptor (1)
- βAR (1)
- γ-Aminobutyric acid (GABA) (1)
Institute
- Institut für Pharmakologie und Toxikologie (230) (remove)
Sonstige beteiligte Institutionen
Linear dose-response relationship for DNA adducts in rat liver from chronic exposure to aflatoxin B1
(1990)
Male F-344 rats were given eH]aßatoxin B1 (AFB1) in the drinking water at three exposure Ievels (0.02, 0.6, 20 J,Lgll, resulting in average dose Ievels of 2.2, 73, 2110 nglkg per day). After 4, 6 and 8 weeks, DNA was ~ted frorn the livers and analyzed for aßatoxin-DNA adducts. Tbe Ievel of DNA adducts did not increase significantly after 4 weeks, indicating that a steady-state for adduct formation and removal had nearly been reached. At 8 weeks, the adduct Ievels were 0.91, 32 and 850 nucleotide-aßatoxin adducts per to' nucleotides, i.e. clearly proportional to the dose. At the high dose Ievel, a near SO% tumor incidence would be expected in a 2-year bioassay with F -344 rats while the low dose used is within the range of estlmated human dietary exposures to aßatoxin in W estem countries. The proportionality seen between exposure and steady-state DNA adduct Ievel is discussed with respect to a linear extrapolation of the tumor risk to low dose.
The formation of \(O^6\)-methyldeoxyguanosine (\(O^6\)-MedGuo) was determined by an immuno-slot-blot assay in DNA of various tissues of F344 rats exposed to N-methyl-N-nitrosourea (MNU) in the drinking waterat 400 ppm for 2 weeks. Although the pyloric region of the glandular stomach is a target organ under these experimental conditions, the extent of DNA methylation was highest in the forestomach (185 \(\mu\)mol \(O^6\)-MedGuojmol guanine). Fundus (91 J.!moljmol guanine) and pylorus (105 J.!moljmol guanine) of the glandular stomach, oesophagus (124 \(\mu\)mol/mol guanine) and duodenum (109 )lmoljmol guanine) showed lower Ievels of \(O^6\) - MedGuo but differed little between each other. Thus, no correlation was observed between target organ specificity and the extent of DNA methylation. This is in contrast to the gastric carcinogen, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), which preferentially alkylates DNA of the pylorus, the main site of induction of gastric carcinomas by this chemical. In contrast to MNU, the nonenzymic decomposition of MNNG is accelerated by thiol compounds (reduced glutathione, L-cysteine), which are present at much higher concentrations in the glandular stomach than in the forestomach and oesophagus. During chronic exposure to MNNG (80 ppm), mucosal cells immunoreactive to 0 6-MedGuo are limited to the luminal surface [Kobori et al. (1988) Carcinogenesis 9:2271-2274]. Although MNU (400 ppm) produced similar Ievels of \(O^6\)-MedGuo in the pylorus, no cells containing methylpurines were detectable by immunohistochemistry, suggesting a more uniform methylation of mucosal cells by MNU than by MNNG. After a single oral dose of MNU (90 mg/kg) cells containing methylpurines were unequivocally identified using antibodies to \(O^6\)-MedGuo and the imidazole-ring-opened product of 7-methyldeoxyguanosine. In the gastric fundus, their distribution was similar to those methylated by exposure to MNNG, whereas the pyloric region contained immunoreactive cells also in the deeper mucosallayers. After a 2-week MNU treatment, the rate of cell proliferation, as determined by bromodeoxyuridine immunoreactivity, was only slightly enhanced in the oesophagus andin the fundus, but markedly in the forestomach and the pyloric region of the glandular stomach. lt is concluded that the overall extent of DNA methylation, the distribution of alkylated cells within the mucosa and the proliferative response all contribute to the organ-specific carcinogenicity of MNU.
Effect of inhalation exposure regimen on DNA binding potency of 1,2-dichloroethane in the rat
(1991)
1 ,2-Dichloroethane (DCE) was reported to be carcinogenic in rats in a long-tenn bioassay using gavage in com oil (24 and 48 mg/kg/day), but not by inhalation (up to 150-250 ppm, 7 h/day, 5 days/week). The daily dose metabolized was similar in the two experiments. In order to address this discrepancy, the genotoxicity of DCE was investigated in vivo under different exposure conditions. Fernale F-344 rats (183-188 g) were exposed to [1,2-14C]DCE in a closed inhalation chamber to either a low, constant concentration (0.3 mg/l = 80 ppm for 4 h) or to a peak concentration (up to 18 mg/1 = 4400 ppm) for a few minutes. After 12 h in the chamber, the dose metabolized under the two conditions was 34 mg/kg and 140 mg/k:g. DNA was isolated from liver and lung and was purified to constant specific radioactivity. DNA was enzymaticaBy hydrolyzed to the 3' -nucleotides which were separated by reverse phase HPLC. Most radioactivity eluted without detectable or with little optical density' indicating that the major part of the DNA radioactivity was due to covalent binding of the test compound. The Ievel of DNA adducts was expressed in the dose-nonnalized units ofthe Covalent Binding Index, CBI = f.Lmol adduct per mol DNA nucleotide/ mmol DCE per kg body wt. In liver DNA, the different exposure regimens resulted in markedly different CBI values of 1.8 and 69, for "constant-low" and ''peak" DCE exposure Ievels. In the Jung, the respective values were 0.9 and 31. It is concluded that the DNA darnage by DCE depends upon the concentration-time profile and that the carcinogenic potency determined in the gavage study should not be used for low-Ievel inhalation exposure.
Styrene-7,8-oxide (SO), the main intennediate metabolite of styrene, induces hyperkeratosis and tumors in the forestomach of rats and mice upon chronic administration by gavage. The aim of this study was to investigate wbether DNA binding could be responsible for the carcinogenic effect observed. [7-\(^3\)H]SO was administered by oral gavage in com oll to male CD rats at two dose levels (1.65 or 240 mg/kg). After 4 or 24 h, forestomach, glandular stomach and Uver were exclsed, DNA was isolated and its radioactivity detennined. At the 4 h time polnt, the DNA radioactivity was below the Iimit of detection in the torestornach and the liver. Expressed in the units of the covalent bindlng Index, CBI = (pmol adduct/mol DNA nucleotide)/(mmol cbemical administeredlkg body wt), the DNA-binding potency was below 2.6 and 2.0 respectively. In the glandular stomach at 4 b, and in most 24 b samples, DNA was slightly radiolabeled. Enzymatic degradation of the DNA and separation by HPLC ofthe normal nucleotides sbowed that the DNA rad.ioactivity represented biosynthetic incorporation of radlolabel into newly synthesized DNA. The Iimit of detection of DNA adducts in the glandular stomach was 1.0. In a second experlment, [7-\(^3\)H]SO was administered by i.p. injection to male 86C3Fl rnice. Liver DNA was analyzed after 2 h. No radloactivity was detectable at a Iimit of detection of CBI < 0.6. In agreement with the relatively long half-life of SO in animals, the cbemical reactivity of SO appears to be too low to result in a detectable production of DNA adducts in an in vivo situation. Upon comparison with the DNA-binding of other carcinogens, a purely genotoxic mechanism of tumorigenJc action of SO is unlikely. The observed tumorigenic potency in the forestomach could be the result of strong tumor promotion by high-dose cytotoxicity foUowed by regenerative hyperplasia.
The intake of known dietary carclnogens was compiled and the cancer risk was estlmated on the basis of carcinogenic potencies in animals as derived from the Carcinogenic Potency Database by Gold and co-workers. The total cancer risk was compared with the number of cancer cases attributed by epidemiologists to dietary factors (one-third of all cancer cases, i.e. -80 000 per one million Jives). Except for alcohol, the known dietary carcinogens could not account for more than a few bundred cancer cases. Tbis was seen both with tbe DNA-reactive carcinogens (beterocyclic aromatic amines, polycyclic aromatic hydrocarbons, N-nitroso compounds, estragole, aflatoxin B., ethyl carbamate, to name the most important factors) as wen as with those carclnogens wbich have not been shown to react with DNA (e.g. caffelc acid and the carcinogeruc metals arsenic and cadmium). Residues and contaminants turned out to be negligible. Among the various pmsibilities to explain the discrepancy we investigated the roJe of ovemutritlon. Dietary restriction in animals is weil known for its strong reducing effect on spontaneous tumor formation. These data can be used to derive a carcinogenic potency for excess macronutrients: tbe tumor incidence seen with the restrlcted animals is taken as a control value and the increased tumor incidence in the animals fed ad libitum is attributed to the additional feed iotake. For excess standard diet in rats, a carcinogenic potency TD50 of 16 glkg/day was deduced from a recent study. Ovemutrition in Switzerland, estimated to be 5.5 kcallkg/day, was converted to excess food (1.9 g/kg/day) and tbe cancer incidence was calculated. The result, 60 000 cancer cases per one million Jives, is provocatively close to the number of cases not explained by the known dietary chemical carcinogens. Mechanistic studies will be required to test our hypothesis and investigate the role of different types of macronutrients in ovemutrition.
2-Acetylaminofluorene (2-AAF) was administered at Ievels of 0, 300 and 600 ppm in the diet for 28 days to female transgenic micc bearing the lacl genein a Iambda vector (Big Blue® mice). The Iambda vector was excised from liver DNA and packaged in vitro into bacteriophage particles which were allowed to infect E. coli bacteria, forming plaques on agar plates. Approximately 10\(^5\) plaques wcre screened per animal for the appearance of a bluc colour, indicative of mutations in the lac/ gcnc which had resulted in an inactive gene product. Background mutation rate was 2.7 x 10\(^{-5}\) (pooled results of two animals, 8 mutant plaques/289 530 plaques). At 300 ppm in the diet, the rate of 3.5 X 10\(^{-5}\)(8/236 300) was not significantly increased over background. At 600 ppm in the dict, the rate increased approximately 3 fold to 7.7 x 10\(^{-5}\) (17 /221240). In comparison to the usual single or 5-day carcinogen exposure regimes, the 4-week exposure protocol allowed the use of much lower dose Ievels 00-1000 fold lower). Overt toxicity could thus be avoided. The daily doses used were somewhat higher than those required in 2-year carcinogenicity studies with 2·AAF.
'lbe mouse skin tumor model was used to investigate whether the Ievel of DNA 8dducts and/or the rate of cell division in the epidermis are indicators of the risk of cancer formation for an individual in an outbred animal popul8tion. A high risk was considered to be reftected by 8 short latency period for the 8ppearance of 8 papilloma. Fernale NMRI mice were treated twice weekly with 2.5 nmol 7 ,12-dimethylbenz[a]antbracene (DMBA) and 3 nmoi12-0-tetradecanoylphorbol-13- 8cetate (TPA) and the appearance of papillomas was registered. The first papilloma 8ppeared after 7.5 weeks. After 17 weeks, when 12 of 14 mice bad 8t least one papilloma, an osmotic minipump deliverlog 5-bromo-2'deoxyuridine (BrdU) was implanted into eacb mouse for 24 h. The mice were killed after 24 h ~d the epidermis was analyzed for D:MBA-nucleotide 8dducts by 32p.postlabeling, for the cell number per unit skin length, and for the labeling index for DNA synthesls. Unexpectedly, D:MBA-nucleotide 8dduct Ievels were highest in those anima1s wbich showed the Iongest latency periods. Adduct Ievels were negatively correlated with the 18beling index, indicating that dilution of adducts by cell division was a predominant factor in determining average adduct concentrations. Individual tumor-latency time was not corTelated with either cell ntunber or labeling index. This could be due to the fact that the measurements only provided 8veraged data and gave no infonnation on the specific situation in clones of premalignant cells. Under the conditions of tbis assay, therefore, neither DNA adduct Ievels nor information on the average kinetics of cell division bad a predidive value for the individual amcer risk withln a group of outbred animals receiving the same treatment
The question addressed was whether Stimulation of cell proliferation could be responsible for tumor induction in the torestornach by styrene 7,8-oxide (SO). Male F344 rats were treated for 4 weeks with 0, 137,275, and 550 mglkg SO by p.o. gavage 3 times/week. Positive controls received 0, 0.5, I, and 2% butylated hydroxyanisole (BHA) in the diet for 4 weeks. Twenty-four h before termination of the experlment, the rats were implanted s.c. with an osmotic minipump deliverlog S-bromo-2'-deoxyuri· dine (BrdU). Cell proliferation in the forestomach was assessed by immunohistochemistry for BrdU incorporated into DNA. Cell number/mm section length and fraction of replicating cells (labeling Index) were determined in 3 domains of the forestomach, the saccus caecus, the midregion, and the prefundic region. With the exception of the prefundic reglon of the low-dose SO group, a significant increase of the labeling index was found in all regions both with SO and BHA. Rats treated with BHA showed, in addition, a dose-dependent increase in number and size of hyperplastic lesions. This was most pronounced in the prefundic region where carcinomas were reported to be localized. In this region, the number of dividing cells/mm section length was increased up to 17-fold. With SO, only marginal morphological changes were occasionally observed, despite the fact that the respective long-term treatment bad been reported to result in a higher carcinoma incidence than treatment with BHA. It ls concluded that the rate of replicating cells alone, numerically expressed by the labeling Index, is an lnsufficient tool for interpretlog the role of cell division in carcinogenesis. It is postulated that SO and BHA induce forestomach tumors via different mechanisms. While hyperplasia in the prefundic region most likely dominates the carcinogenicity of BHA, a mechanism combining marginal genotoxicity with strong promotion by increased cell proliferation appears to be involved in the tumorigenic action of SO.
The detection Iimit of the lacl transgenic mouse mutagenicity assay lies, in practice, at approximately a 50-100% increase in mutant frequency in treated animals over controls. The sensitivity of this assay in detecting genotoxins can be markedly improved by subchronic rather than acute application of the test compound. The lac/ transgenic mouse mutagenicity assay was compared quantitatively to rodent carcinogenicity tests and to presently used in vivo mutagenicity assays. With the genotoxic carcinogens tested thus far, a rough correlation between mutagenic potency and carcinogenic potency was observed: on average, to obtain a doubling in lacl mutant frequency the mice bad to be treated with a total dose equal to 50 times the TD50 daily dose Ievel. This total dose could be administered eilher at a high dose rate within a few days or, preferably, at a low dose rate over several weeks. This analysis also indicated that a lacl experiment using a 250-day exposure period would give a detection Iimit approximately equal to that of a long-term carcinogenicity study. In comparison to the micronucleus test or the chromosome aberration assay, acute sturlies with the presently available lacl system offered no increase in sensitivity. However, subchronic lacl sturlies (3-4-month exposure) resulted in an increase in sensitivity over the established tests by 1-2 orders of magnitude (shown with 2-acetylaminofluorene, N-nitrosomethylamine, N-nitrosomethylurea and urethane). 1t is concluded that a positive result in the lacl test can be highly predictive of carcinogenicity butthat a negative result does not provide a large margin of safety.
Desensitization of N-fonnyl peptide chemoattractant receptors (FPR) in human neutrophils is thought to be achieved by lateral segregation of receptors and G proteins within the plane of the plasma membrane resulting in an interruption of the signalling cascade. Direct coupling of FPR to membrane skeletal actin appears to be the basis of this process~ however, the molecular mechanism is unknown. In this study we investigated the effect of energy depletion on formation of FPR-membrane skeleton complexes. In addition the effect of the protein kinase C inhibitor stauroporine and the phosphatase inhibitor okadaic acid on coupling of FPR to the membrane skeletonwas studied. Human neutrophils were desensitized using the photoreactive agonist N-formy1-met-leu-phe-1ys-N'[\(^{125}\)I]2(p-azidosalicylamido)ethyl-1,3'-dithiopropionate (fMLFK-[\(^{125}\)I]ASD) after ATP depletion with NaF or after incubation with the respective inhibitors. The interaction of FPR with the membrane skeleton was studied by Sedimentation of the membrane skeleton-associated receptors in sucrose density gradients. Energy depletion of the cells markedly inhibited the formation of FPR-membrane skeleton complexes. This does not appear tobe related to inhibition of protein phosphorylation due to ATP depletion because inhibition of protein kinases and phosphatases bad no significant effect on coupling of FPR to the membrane skeleton. We conclude, therefore, that coupling of FPR to the membrane skeleton is an energy,dependent process which does not appear to require modification of the receptor protein by phosphorylation.
Desensitization of N-formyl peptide chemoattractant receptors (FPR) in human neutrophils results in association of these receptors to the membrane skeleton. This is thought to be the critical event in the lateral segregation of receptors and guanyl nucleotide-binding proteins (G proteins) within the plane of the plasma membrane resulting in an interruption of the signaling cascade. In this study we probed the interaction of FPR with G protein in human neutrophils that were desensitized to various degrees. Human neutrophils were desensitized using the photoreactive agonist N-formyl-met-leu-phelys- N\(^\epsilon\)-[\(^{125}\)I]2(p-azidosalicylamido )ethyl-1 ,3 '-dithiopropionate (/MLFK-[\(^{125}\)I]ASD). The interaction if FPR with G protein was studied via a reconstitution assay and subsequent analysis of FPR-G protein complexes in sucrose density gradients. FPR-G protein complexes were reconstituted with solubilized FPR from partially and fully desensitized neutrophils with increasing concentrations of Gi purified from bovine brain. The respective EC\(_{50}\) values for reconstitution were similar to that determined for FPR from unstimulated neutrophils (Bommakanti RK et al., J Bio[ Chem 267: 757~7581, 1992). We conclude, therefore, that the affinity of the interaction of FPR with G protein is not affected by desensitization, consistent with the model of lateral segregation of FPR and G protein as a mechanism of desensitization.
Signal transduction via receptors for N-formylmethionyl peptide chemoattractants (FPR) on human neutrophils is a highly regulated process which involves participation of cytoskeletal elements. Evidence exists suggesting that the cytoskeleton and/or the membrane skeleton controls the distributJon of FPR in the plane of the plasma membrane, thus controlling the accessibility of FPR to different proteins in functionally distinct domains. In desensitized cells, FPR are restricted todomains which are depleted of G proteins but enriched in cytoskeletal proteins such as actin and fodrin. Thus, the G protein signal transduction partners of FPR become inaccessible to the agonist-occupied receptor, preventing cell activation. The mechanism of interaction of FPR with the membrane skeleton is poorly understood but evidence is accumulating that suggests a direct binding of FPR (and other receptors) to cytoskeletal proteins such as actin.
The cytoskeleton and/or membrane skeleton has been implicated in the regulation of N-formyl peptide receptors. The coupling of these chemotactic receptors to the membrane skeleton was investigated in plasma membranes from unstimulated and desensitized human neutrophils using the photoreactive agonist N-formyl-met-leu-phelys-N\(^6\)-[\(^{125}\)I]2(p-azidosalicylamido)ethyl-1,3'-dithiopropionate (fMLFK-[\(^{125}\)I]ASD). When membranes of unstimulated cells were solubilized in Triton-X 100, a detergent that does not disrupt actin filaments, only 50% of the photoaffinity-labeled receptors were solubilized sedimenting in sucrose density gradients at a rate consistent with previous reports. The remainder were found in the pellet fraction along with the membrane skeletal actin. Solubilization of the membranes in the presence of p-chloromercuriphenylsulfonic acid, elevated concentrations of KCI, or deoxyribonuclease I released receptors in parallel with actin. When membranes from neutrophils, desensitized by incubation with fMLFK-e 251]ASD at 15°C, were solubilized, nearly all receptors were recovered in the pellet fraction. lncubation of cells with the Iigand at 4°C inhibited desensitization partially and prevented the conversion of a significant fraction of receptors to the form associated with the membrane skeletal pellet. ln these separations the photoaffinity-labeled receptors not sedimenting to the pellet cosedimented with actin. Approximately 25% of these receptors could be immunosedimented with antiactin antibodies suggesting that N-formyl peptide receptors may interact directly with actin. These results are consistent with a regulatory role for the interaction of chemotactic N-formyl peptide receptors with actin of the membrane skeleton.
When human neutrophils become desensitized to formyl peptide chemoattractants, the receptors (FPR) for these peptides are converted to a high affinity, GTP-insensitive form that is associated with the Triton X-1 00- insoluble membrane skeleton from surface membrane domains. These domains are actin and fodrin-rich, but G protein-depfeted suggesting that FPR shuttling between G protein-enriched and depleted domains may control signal transduction. Todetermine the molecular basis for FPR interaction with the membrane skeleton, neutrophil subcellular fractions were screened for molecules that could bind photoaffinity-radioiodinated FPR solubilized in Triton X-1 00. These receptors showed a propensity to bind to a 41- to43-kDa proteinband on nitrocelluloseoverlays of SOS-PAGE-separated cytosol and plasma membrane fractions of neutrophils. This binding, as weil as FPR binding to purified neutrophil actin, was inhibited 50% by 0.6 \(\mu\)M free neutrophil cytosolic actin. Addition of greater than 1 \(\mu\)M G-actin to crude or lectin-purified Triton X-1 00 extracts of FPR from neutrophil membranes increased the sedimentationrate of a significant fraction of FPR two to three fold as measured by velocity sedimentation in Triton X-1 00-containing linear sucrose density gradients. Addition of anti-actin antibodies to FPR extracts caused a concentration-dependent immunoprecipitation of at least 65% of the FPR. More than 40% of the immunoprecipitated FPR was specifically retained on protein A affinity matrices. Membrane actin was stabilized to alkaline washing when membranes were photoaffinity labeled. Conversely, when purified neutrophil cytosolic actinwas added to membranes or their digitonin extracts, after prior depletion of actin by an alkaline membrane wash, photoaffinity labeling of FPR was increased two- to fourfold with an EC\(_{50}\) of approximately 0.1 \(\mu\)M actin. We conclude that FPR from human neutrophils may interact with actin in membranes to form Triton X-1 00-stable physical complexes. These complexes can accept additional G-actin monomers to form higher order molecular complexes. Formation of FPR-actin complexes in the neutrophil may play a role in the regulation of chemoattractantinduced activation or actin polymerization.